A phase 3 trial found that ubrogepant, given during the premonitory phase of migraine, improved common warning symptoms such as fatigue, light and sound sensitivity, and neck pain. These benefits were observed as early as one hour post-treatment, suggesting early intervention can reduce migraine burden.
from News Medical Medical Research News Feed https://ift.tt/LQvIcVy
0 Comments